SANUWAVE (SNWV)
Builds non-contact ultrasound systems and applicators for wound care.
Something off on this page? Send us feedback.
Develops UltraMIST, a non-contact ultrasound system for acute and chronic wound treatment. Revenue is centered on systems and sterile single-use applicators, with one medical-device segment and operations primarily in the United States.
UltraMIST is the current commercial center: a low-frequency, non-thermal ultrasound system that delivers energy through a fluid mist without contact. The portfolio is focused on wound healing and debridement, while PACE has been sold or disposed and is not a current product.
Revenue comes from the installed systems and sterile single-use applicators used with each treatment. Reporting is organized as one medical-device segment, with business activity primarily in the United States.
Execution depends on clinical adoption, provider reimbursement economics, and a small commercial organization scaling a focused wound-care platform. The filing also identifies unremediated material weaknesses in financial reporting controls, making accounting-control remediation a structural operating dependency.
Company facts
Categories
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior target | Target |
|---|---|---|---|---|
| Oct 7, 2025 | Roth Capital | Target | $55 | $53 |
| Sep 3, 2025 | Northland Securities | Target | $55 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $9.4M · Total debt $20.7M · Total assets $36.6M · Shareholders' equity $2.8M
- Revenue
- $9.7M
- Operating income
- −$280.0K
- Net income
- −$682.0K
No dividends on record.
| Institutions63 holders · as of Mar 31, 2026 | 48.36% | 4.16M shares | |
| Insiders6 holders · as of Jun 12, 2025 | 4.79% | 412.3K shares | |
| Strategic holders1 holder · as of Dec 15, 2025 | 0.77% | 66.0K shares | |
| Otherremainder | 46.08% | 3.96M shares |
8.60M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Opaleye Management Inc.Institution | 11.41% | 981,267 | 13Fas of Mar 31, 2026 |
BlackRock, Inc.Institution | 5.60% | 481,540 | 13Fas of Mar 31, 2026 |
Awm Investment Company, Inc.Institution | 5.28% | 454,550 | 13Fas of Mar 31, 2026 |
Anthony Michael StolarskiInsiderdirector | 4.09% | 351,786 | Form 4filed Jun 12, 2025 ↗ |
Praetorian PR LLCInstitution | 4.07% | 350,000 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 1, 2026 | Opaleye Management Inc. | 10 percent owner | −10,581 | $16.11 |
| Apr 30, 2026 | Opaleye Management Inc. | 10 percent owner | −25,000 | $16.15 |
| Apr 29, 2026 | Opaleye Management Inc. | 10 percent owner | −24,360 | $17.25 |
| Apr 28, 2026 | Opaleye Management Inc. | 10 percent owner | −46,288 | $18.47 |
| Apr 17, 2026 | Opaleye Management Inc. | 10 percent owner | −16,267 | $20.46 |
- Solventum
V.A.C. and Prevena set the NPWT benchmark in wound care
- Smith & Nephew (ADR)
PICO, RENASYS, SANTYL, and skin substitutes span wound care
- Organogenesis
Regenerative skin substitutes for chronic and acute wound closure
- MiMedx
Placental tissue products for chronic and hard-to-heal wounds
- Integra LifeSciences
Dermal matrices and scaffolds for wound reconstruction
- Bioventus
SonicOne ultrasonic debridement overlaps directly with wound-bed prep
- Spectral AI
DeepView imaging guides burn and wound-treatment decisions
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| SANUWAVE | $4.44 | −3.48% | $38.3M | 4.9 | 6.0 | 0.9 | −4.2% |
| Solventum | $91.90 | −0.01% | $15.91B | 11.2 | 13.6 | 1.9 | +2.2% |
| Smith & Nephew (ADR) | $28.58 | −0.34% | $12.04B | 19.0 | — | 1.9 | +3.7% |
| Organogenesis | $1.68 | +0.56% | $214.9M | — | — | 0.5 | −56.7% |
| MiMedx | $4.56 | +1.00% | $663.2M | 113.8 | 107.3 | 1.9 | −34.7% |
| Integra LifeSciences | $16.88 | +0.42% | $1.31B | — | 6.6 | 0.8 | +0.8% |
| Bioventus | $14.30 | −0.38% | $973.5M | 18.7 | 17.8 | 1.7 | +3.8% |
| Spectral AI | $1.61 | +2.55% | $49.8M | — | — | 3.3 | −30.4% |
| Median | 18.8 | 15.7 | 1.9 | +0.8% |